Sunifiram
Cognition, Memory
No human trial and no toxicology study has ever been run. A half-life of at least 4 h has been reported in Sprague-Dawley rats; every human figure circulating online is extrapolated from rodent work or anecdote.
In short
- No human study of any kind has ever been published — not efficacy, not safety, not pharmacokinetics, not toxicology.
- Every human dose, onset, and duration figure circulating online is extrapolated from rodent work or from anecdote.
- Rodent data shows cognition-enhancing activity at very low doses relative to piracetam, acting through AMPA-mediated signalling.
- Reported to be roughly 1,000× more potent by weight than piracetam in animal models, which makes measurement error correspondingly more consequential.
- Research compound only. Not approved anywhere, for anything.
Structure
How it works
Sunifiram (DM-235) is a piperazine derivative characterised alongside unifiram (DM-232) as a cognition enhancer in rodents. It is frequently grouped with the racetams but is structurally distinct.
The mechanism described in preclinical work involves enhancement of AMPA receptor-mediated glutamatergic transmission, with downstream effects on long-term potentiation and acetylcholine release in the hippocampus. Some work implicates glycine-binding site activity at the NMDA receptor.
All of this is rodent tissue and rodent behaviour. There is no human mechanistic data.
What the research shows
In rodents, sunifiram reversed amnesia induced by scopolamine and other agents across passive-avoidance and object-recognition tasks, at doses far below those required for piracetam.
There are no human results to report, because no human study has been conducted.
Dosing in the literature
Figures below are quoted from published studies, with the species or population they were measured in. They are records of what was studied, not recommendations.
| Studied in | Amount | Route | Source |
|---|---|---|---|
| Mouse — antiamnesic behavioural models | Approximately 0.001–0.1 mg/kg | intraperitoneal or oral | PubMed |
| Rat — pharmacokinetics (the only PK data that exists) | Half-life at least 4 h in Sprague-Dawley rats | — | PubMed |
Commonly reported ranges
These are amounts people report using. They are not from any study, have not been evaluated for safety, and are reproduced here only because they circulate widely and are better seen alongside the evidence than instead of it.
| Reported by | Amount | Route |
|---|---|---|
| Commonly reported | 5–10 mg, once or twice daily | oral or sublingual |
There is no human dose. The community figures here have no study behind them at all, and the compound has never undergone toxicology testing in any species at any dose — meaning no maximum tolerated dose is known. Rodent figures are per kilogram of rodent and do not scale to humans by body-weight ratio.
Handling and storage
Supplied as a powder or capsules in the research-chemical market. Because the reported active amounts are small, volumetric dosing is often described as a way to avoid weighing errors on scales that lack the necessary resolution.
No route, timing, or duration has been established in humans.
Side effects
No safety data exists. This is not shorthand for "appears safe" — no toxicology study has been performed in any species, so there is no established maximum tolerated dose, no organ-toxicity screening, and no chronic exposure data.
Community reports mention headache, insomnia, irritability, and increased perspiration. These are uncontrolled self-reports.
The general class concern for AMPA-potentiating compounds is excitotoxicity and reduced seizure threshold. Whether sunifiram carries it is unknown, because the studies that would answer that have not been done.
Combinations
No interaction data exists. Combining an uncharacterised AMPA-active compound with other glutamatergic or cholinergic agents means stacking two unknowns.
Community reports commonly pair it with a choline source on the assumption of increased cholinergic demand — an assumption imported from the racetams rather than demonstrated for this compound.
Research status
The foundational publication is Ghelardini et al. (2002), characterising DM-232 and DM-235 as cognition enhancers in rodents. Subsequent work explored AMPA and NMDA glycine-site mechanisms.
As of 2016 the compound had been subjected to neither toxicology testing nor any human clinical trial, and nothing published since has changed that.
Legal status
Not approved for human use in any jurisdiction. Not scheduled as a controlled substance in most countries, which reflects the absence of abuse-potential assessment rather than any safety determination. Sold labelled for research use only.
WADA status
Not specifically listed. Falls under WADA class S0 — any pharmacological substance not approved by any governmental regulatory health authority for human therapeutic use is prohibited in sport. Treat it as prohibited.
Conclusion
Sunifiram is the clearest example in this library of a compound with an interesting preclinical mechanism and a complete absence of human data. It has never been given to a human under study, and it has never been through toxicology.
If you use it you are not replicating a protocol; you are the first documented data point, without monitoring.
Sources
Track your own Sunifiram protocol
Peppers logs your doses, models your levels from this half-life, tracks your vials and tells you when you will run out. Free on iPhone.
Reference and educational information only. Not medical advice. Nothing here diagnoses, treats, or prescribes, and nothing here is a recommendation to use any compound. The compounds described are research chemicals and are not approved for human consumption. Legal and anti-doping status change — the review date above is when these claims were last checked. Talk to a qualified clinician about anything you intend to take.